BioMarin Expands Hub Operations

BioMarin Manufacturing Ireland, a subsidiary of BioMarin Pharmaceutical Inc. has announced proposed expansion of its operations with the creation of up to 50 new jobs in its Dublin Global Commercial Operations Hub; the company has also received European Commission approval of VIMIZIM, an enzyme replacement drug for the treatment of MPS IVA, a lysosomal storage disorder.

The Dublin operation has responsibility for international supply chain, logistics and high level commercial decision making, including price, distribution and third party contracts for the launch of VIMIZIM.  The company will recruit senior accounting, finance, customer service and marketing positions.

This expansion complements the growth in BioMarin’s biopharma manufacturing facility in Shanbally, Co. Cork which is expected to grow to 140 employees by 2015 to support the anticipated commercial demand of VIMIZIM. 

BioMarin expects to have a combined total employment of approximately 200 people in Ireland by the end of 2017. This investment is supported by Department of Jobs, Enterprise and Innovation through IDA Ireland.

James Lennertz, VP & GM BMIL and EUMEA Commercial Operations, BioMarin said “Ireland is an ideal business environment, which lets us focus on what we do best—targeting diseases like Morquio A syndrome that lack effective drug therapies and affect relatively few people, many of whom are children.  The expansion of BioMarin’s Global Commercial Operation in Dublin is an essential part of our strategy in providing therapies that are the first or best of their kind.”